Alliance Pharma’s buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma was transformational, doubling the size of the company and providing a more internationally-oriented business. The enlarged group is also a more attractive and credible partner for in– licensing and M&A opportunities. 2017 is building on the foundations laid in 2016 with international growth brands driving performance, which will be boosted by the upcoming regulatory approval of Diclectin.
If you'd like to be introduced to the team at Alliance Pharma Plc, get in touch.Request a meeting